# EDGAR Filing Document

**Accession Number:** 0001422143
**File Stem:** 0001193125-26-257777
**Filing Date:** 2026-6
**Character Count:** 20094
**Document Hash:** 035814c4675dd67cd6b36129cfdd87ec
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001193125-26-257777.hdr.sgml**: 20260622

**ACCESSION NUMBER**: 0001193125-26-257777

**CONFORMED SUBMISSION TYPE**: S-8

**PUBLIC DOCUMENT COUNT**: 14

**FILED AS OF DATE**: 20260604

**DATE AS OF CHANGE**: 20260604

**EFFECTIVENESS DATE**: 20260604

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Kura Oncology, Inc.
- **CENTRAL INDEX KEY:** 0001422143
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 611547851
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** S-8
- **SEC ACT:** 1933 Act
- **SEC FILE NUMBER:** 333-296511
- **FILM NUMBER:** 261066078

**BUSINESS ADDRESS:**
- **STREET 1:** 4930 DIRECTORS PLACE, SUITE 500
- **CITY:** SAN DIEGO
- **STATE:** CA
- **ZIP:** 92121
- **BUSINESS PHONE:** (858) 500-8800

**MAIL ADDRESS:**
- **STREET 1:** 4930 DIRECTORS PLACE, SUITE 500
- **CITY:** SAN DIEGO
- **STATE:** CA
- **ZIP:** 92121

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** ZETA ACQUISITION CORP III
- **DATE OF NAME CHANGE:** 20071227

**As filed with the Securities and Exchange Commission on June 4, 2026**

**Registration No. 333-**

------

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

------

**FORM S-8**

**REGISTRATION STATEMENT**

***UNDER THE SECURITIES ACT OF 1933***

------

**KURA ONCOLOGY, INC.**

**(Exact name of registrant as specified in its charter)**

------

---

| | |
|:---|:---|
| **Delaware** | **61-1547851** |
| **(State or other jurisdiction of<br>incorporation or organization)** | **(I.R.S. Employer<br>Identification No.)** |
| **4930 Directors Place, Suite 500, San Diego, CA** | **92121** |
| **(Address of Principal Executive Offices)** | **(Zip Code)** |

---

**Kura Oncology, Inc. Amended and Restated 2014 Equity Incentive Plan** 

**Kura Oncology, Inc. Amended and Restated 2015 Employee Stock Purchase Plan** 

 **(Full titles of the plans)**

**Troy E. Wilson, Ph.D., J.D.**

**President and Chief Executive Officer** 

**Kura Oncology, Inc.** 

**4930 Directors Place, Suite 500**

**San Diego, California 92121**

 **(858) 500-8800**

**(Name, address, and telephone number, including area code, of agent for service)**

------

***Copies to:*** 

---

| | |
|:---|:---|
| **Charles J. Bair, Esq.**<br>**Cooley LLP**<br>**10265 Science Center Drive**<br>**San Diego, California 92121**<br>**(858) 550-6000** | **Teresa Bair**<br>**Chief Legal Officer and Secretary**<br>**Kura Oncology, Inc.** <br>**4930 Directors Place, Suite 500**<br>**San Diego, California 92121** <br>**(858) 500-8800** |

---

------

Indicate by check mark whether the Registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of "large accelerated filer," "accelerated filer," "smaller reporting company," and "emerging growth company" in Rule 12b-2 of the Exchange Act.

---

| | | | |
|:---|:---|:---|:---|
| Large accelerated filer | ☐ | Accelerated filer | ☐ |
| Non-accelerated filer | ☒ | Smaller reporting company | ☒ |
|  |  | Emerging growth company | ☐ |

---

If an emerging growth company, indicate by check mark if the Registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ☐

------

**REGISTRATION OF ADDITIONAL SECURITIES**

Kura Oncology, Inc. (the "***Registrant***") has prepared this Registration Statement on Form S-8 (this "***Registration Statement***") in accordance with the requirements of Form S-8 under the Securities Act of 1933, as amended, to register (i) 6,500,000 additional shares of the Registrant's Common Stock ("***Common Stock***") issuable under the Kura Oncology, Inc. Amended and Restated 2014 Equity Incentive Plan (the "***2014 Plan***"), pursuant to an increase in the number of shares of Common Stock reserved for issuance under the 2014 Plan, and (ii) 2,500,000 additional shares of Common Stock issuable under the Kura Oncology, Inc. Amended and Restated 2015 Employee Stock Purchase Plan (the "***2015 ESPP***" and, together with the 2014 Plan, the "***Plans***"), pursuant to an increase in the number of shares of Common Stock reserved for issuance under the 2015 ESPP.

**INCORPORATION OF DOCUMENTS BY REFERENCE**

This Registration Statement is being filed for the purpose of increasing the number of securities of the same class as other securities for which a Registration Statement of the Registrant on Form S-8 relating to the same employee benefit plans is effective.

The Registrant previously registered shares of its Common Stock for issuance under the Plans under Registration Statements on Form S-8 filed with the Securities and Exchange Commission on [<u>April 17, 2015</u>](https://www.sec.gov/Archives/edgar/data/1422143/000119312515136158/d909001ds8.htm) (File No. 333-203504), [<u>March 17, 2016</u>](https://www.sec.gov/Archives/edgar/data/1422143/000156459016015000/kura-s8_20160317.htm) (File No. 333-210260), [<u>March 14, 2017</u>](https://www.sec.gov/Archives/edgar/data/1422143/000156459017004296/kura-s8.htm) (File No. 333-216683), [<u>March 12, 2018</u>](https://www.sec.gov/Archives/edgar/data/1422143/000156459018005302/kura-s8.htm)(File No. 333-223591), [<u>March 5, 2019</u>](https://www.sec.gov/Archives/edgar/data/1422143/000156459019006283/kura-s8.htm) (File No. 333-230075), [<u>February 25, 2020</u>](https://www.sec.gov/Archives/edgar/data/1422143/000156459020006407/kura-s8.htm) (File No. 333-236621), [<u>February 24, 202</u><u>1</u>](https://www.sec.gov/Archives/edgar/data/1422143/000156459021007909/kura-s8.htm) (File No. 333-253441), [<u>February 24, 2022</u>](https://www.sec.gov/Archives/edgar/data/1422143/000156459022006787/kura-s8.htm) (File No. 333-263000), [<u>February 24, 2023</u>](https://www.sec.gov/Archives/edgar/data/1422143/000095017023004192/kura_s8_02-23-2023.htm) (File No. 333-269974), [<u>June 2, 2023</u>](https://www.sec.gov/Archives/edgar/data/1422143/000095017023026101/kura_s8_06-02-2023.htm) (File No. 333-272389), [<u>June 7, 2024</u>](https://www.sec.gov/Archives/edgar/data/1422143/000095017024070722/kura_s8_06-07-2024.htm) (File No. 333-280050) and [<u>June 6, 2025</u>](https://www.sec.gov/Archives/edgar/data/1422143/000095017025083276/kura-20250606.htm) (File No. 333-287866). Pursuant to General Instruction E to Form S-8, this Registration Statement hereby incorporates by reference the contents of the Registration Statements referenced above.

**Item 8. Exhibits.**

---

| | |
|:---|:---|
| **Exhibit<br>Number** | **Description** |
| 4.1 | [<u>Amended and Restated Certificate of Incorporation of the Registrant, as amended (incorporated by reference to Exhibit 3.1 of the Registrant's Form 8-K filed on June 14, 2017).</u>](https://www.sec.gov/Archives/edgar/data/1422143/000156459017012532/kura-ex31_7.htm) |
| 4.2 | [<u>Amended and Restated Bylaws of the Registrant (incorporated by reference to Exhibit 99.1 of the Registrant's Form 8-K filed on January 29, 2026).</u>](https://www.sec.gov/Archives/edgar/data/1422143/000119312526029705/d18498dex991.htm) |
| 4.3 | [<u>Form of Common Stock Certificate of the Registrant (incorporated by reference to Exhibit 4.1 of the Registrant's Form 8-K filed on March 12, 2015, containing items 1.01, 2.01, 3.02, 4.01, 5.01, 5.02, 5.03, 5.06 and 9.01).</u>](https://www.sec.gov/Archives/edgar/data/1422143/000119312515089245/d885721dex41.htm) |
| 5.1 | [<u>Opinion of Cooley LLP.</u>](kura-ex5_1.htm)**\*** |
| 23.1 | [<u>Consent of Independent Registered Public Accounting Firm.</u>](kura-ex23_1.htm)**\*** |
| 23.2 | [<u>Consent of Cooley LLP. Reference is made to Exhibit 5.1.</u>](kura-ex5_1.htm)**\*** |
| 24.1 | [<u>Power of Attorney. Reference is made to the signature page hereto.</u>](#poa)**\*** |
| 99.1 | [<u>Kura Oncology, Inc. Amended and Restated 2014 Equity Incentive Plan and Forms of Stock Option Agreement, Notice of Exercise and Stock Option Grant Notice thereunder (incorporated by reference to Exhibit 99.1 of the Registrant's Form 8-K filed on June 4, 2026).</u>](https://www.sec.gov/Archives/edgar/data/1422143/000119312526257368/kura-ex99_1.htm) |
| 99.2 | [<u>Form of Restricted Stock Purchase Agreement and Restricted Stock Purchase Award Notice under the Kura Oncology, Inc. Amended and Restated 2014 Equity Incentive Plan (incorporated by reference to Exhibit 10.2 of the Registrant's Form 8-K filed on March 12, 2015, containing items 1.01, 2.01, 3.02, 4.01, 5.01, 5.02, 5.03, 5.06 and 9.01).</u>](https://www.sec.gov/Archives/edgar/data/1422143/000119312515089245/d885721dex102.htm) |
| 99.3 | [<u>Form of Restricted Stock Unit Award Grant Notice and Restricted Stock Unit Award Agreement under the Kura Oncology, Inc. Amended and Restated 2014 Equity Incentive Plan (incorporated by reference to Exhibit 10.22 of the Registrant's Form 10-K filed on February 23, 2023).</u>](https://www.sec.gov/Archives/edgar/data/1422143/000095017023004107/kura-ex10_22.htm) |
| 99.4 | [<u>Kura Oncology, Inc. Amended and Restated 2015 Employee Stock Purchase Plan (incorporated by reference to Exhibit 99.2 of the Registrant's Form 8-K filed on June 4, 2026).</u>](https://www.sec.gov/Archives/edgar/data/1422143/000119312526257368/kura-ex99_2.htm) |
| 107 | [<u>Filing Fee Table</u>](kura_exfilingfees.htm)**\*** |
| <br>\* Filed herewith | <br>\* Filed herewith |

---

------

**SIGNATURES**

Pursuant to the requirements of the Securities Act of 1933, as amended, the Registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this Registration Statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of San Diego, State of California, on June 4, 2026.

---

| | |
|:---|:---|
| **Kura Oncology, Inc.** | **Kura Oncology, Inc.** |
| By: | /s/ Troy E. Wilson, Ph.D., J.D. |
|  | Troy E. Wilson, Ph.D., J.D. |
|  | **President and Chief Executive Officer** |

---

**POWER OF ATTORNEY**

KNOW ALL PERSONS BY THESE PRESENTS, that each person whose signature appears below constitutes and appoints Troy E. Wilson, Ph.D., J.D. and Thomas Doyle, and each of them, as his or her true and lawful attorneys-in-fact and agents, each with the full power of substitution, for him or her and in his or her name, place or stead, in any and all capacities, to sign any and all amendments to this Registration Statement (including post-effective amendments), and to file the same, with all exhibits thereto and other documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorneys-in-fact and agents, and each of them, full power and authority to do and perform each and every act and thing requisite and necessary to be done in and about the premises, as fully to all intents and purposes as he or she might or could do in person, hereby ratifying and confirming all that said attorneys-in-fact and agents, or their or his or her substitute or substitutes, may lawfully do or cause to be done by virtue hereof.

Pursuant to the requirements of the Securities Act of 1933, as amended, this Registration Statement has been signed by the following persons in the capacities and on the dates indicated.

---

| | | |
|:---|:---|:---|
| **Signature** | **Title** | **Date** |
| /s/ Troy E. Wilson, Ph.D., J.D. | President, Chief Executive Officer and <br>Chairman of the Board of Directors | June 4, 2026 |
| **Troy E. Wilson, Ph.D., J.D.** | *(Principal Executive and Financial Officer)* |  |
| /s/ Thomas Doyle | Senior Vice President, Finance & Accounting | June 4, 2026 |
| **Thomas Doyle** | *(Principal Accounting Officer)* |  |
| /s/ Helen Collins, M.D. | Director | June 4, 2026 |
| **Helen Collins, M.D.** |  |  |
| /s/ Faheem Hasnain | Director | June 4, 2026 |
| **Faheem Hasnain** |  |  |
| /s/ Thomas Malley | Director | June 4, 2026 |
| **Thomas Malley** |  |  |
| /s/ Diane Parks | Director | June 4, 2026 |
| **Diane Parks** |  |  |
| /s/ Carol Schafer | Director | June 4, 2026 |
| **Carol Schafer** |  |  |
| /s/ Mary Szela | Director | June 4, 2026 |
| **Mary Szela** |  |  |
| /s/ Michael Vasconcelles, M.D. | Director | June 4, 2026 |
| **Michael Vasconcelles, M.D.** |  |  |

---

------

## Exhibit 5.1

---

| | |
|:---|:---|
| &nbsp;&nbsp;![img190708051_0.jpg](img190708051_0.jpg) | &nbsp;&nbsp;**Exhibit 5.1**<br>|
| &nbsp;&nbsp;Charles J. Bair<br>+1 858 550 6142<br>cbair@cooley.com |  |

---

June 4, 2026

Kura Oncology, Inc.

4930 Directors Place, Suite 500

San Diego, CA 92121

**Re: Kura Oncology, Inc.**

Ladies and Gentlemen:

We have acted as counsel to Kura Oncology, Inc., a Delaware corporation (the "***Company***"), in connection with the filing by the Company of a Registration Statement on Form S-8 (the "***Registration Statement***") with the Securities and Exchange Commission (the "***Commission***"), covering the offering of up to 9,000,000 shares (the "***Shares***") of the Company's Common Stock, par value $0.0001 per share ("***Common Stock***"), consisting of (i) 6,500,000 shares of Common Stock issuable pursuant to the Company's Amended and Restated 2014 Equity Incentive Plan (the "***Incentive Plan***") and (ii) 2,500,000 shares of Common Stock issuable pursuant to the Company's Amended and Restated 2015 Employee Stock Purchase Plan (together with the Incentive Plan, the "***Plans***").

In connection with this opinion, we have examined and relied upon (a) the Registration Statement and related prospectuses, (b) the Plans, (c) the Company's certificate of incorporation and bylaws, each as currently in effect, and (d) such other records, documents, opinions, certificates, memoranda and instruments as in our judgment are necessary or appropriate to enable us to render the opinion expressed below. We have assumed the genuineness of all signatures, the authenticity of all documents submitted to us as originals, the conformity to originals of all documents submitted to us as copies, the accuracy, completeness and authenticity of certificates of public officials, and the due authorization, execution and delivery of all documents by all persons other than the Company. As to certain factual matters, we have relied upon a certificate of an officer of the Company and have not independently verified such matters.

Our opinion is expressed only with respect to the General Corporation Law of the State of Delaware. We express no opinion to the extent that any other laws are applicable to the subject matter hereof and express no opinion and provide no assurance as to compliance with any federal or state securities law, rule or regulation.

On the basis of the foregoing, and in reliance thereon, we are of the opinion that the Shares, when sold and issued in accordance with the Plans, the Registration Statement and the related prospectuses, will be validly issued, fully paid and nonassessable (except as to Shares issued pursuant to deferred payment arrangements, which will be fully paid and nonassessable when such deferred payments are made in full).

This opinion is limited to the matters expressly set forth in this letter, and no opinion has been or should be implied, or may be inferred, beyond the matters expressly stated. This opinion speaks only as to law and facts in effect or existing as of the date hereof, and we have no obligation or responsibility to update or supplement this opinion to reflect any facts or circumstances that may hereafter come to our attention or any changes in law that may hereafter occur.

We consent to the filing of this opinion as an exhibit to the Registration Statement. In giving such consent, we do not thereby admit that we are in the category of persons whose consent is required under Section 7 of the Securities Act of 1933, as amended, or the rules and regulations of the Commission thereunder.

Sincerely,

Cooley LLP

---

| | |
|:---|:---|
| &nbsp;&nbsp;By: | &nbsp;&nbsp;/s/ Charles J. Bair |
|  | &nbsp;&nbsp;Charles J. Bair |

---

10265 SCIENCE CENTER DRIVE, SAN DIEGO, CA 92121 T: (858) 550-6000 F: (858) 550-6420 WWW.COOLEY.COM

------

## Exhibit 23.1

**Exhibit 23.1**

**Consent of Independent Registered Public Accounting Firm**

We consent to the incorporation by reference in the Registration Statement (Form S-8) pertaining to the Kura Oncology, Inc. Amended and Restated 2014 Equity Incentive Plan and the Kura Oncology, Inc. Amended and Restated 2015 Employee Stock Purchase Plan of our report dated March 5, 2026, with respect to the financial statements of Kura Oncology, Inc. included in its Annual Report (Form 10-K) for the year ended December 31, 2025, filed with the Securities and Exchange Commission.

/s/ Ernst & Young LLP

San Diego, California

June 4, 2026

------

## Ex-Filing

?xml version='1.0' encoding='ASCII'? EX-FILING FEES

**Exhibit 107**

## Calculation of Filing Fee Tables

## Form S-8
(Form Type)

Kura Oncology, Inc.

(Exact Name of Registrant as Specified in its Charter)

<u>Table 1: Newly Registered Securities</u>

---

| | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|
| **Security**<br>**Type** | **Security**<br>**Class**<br>**Title** | **Fee**<br>**Calculation**<br>**Rule** | **Amount**<br>**Registered(1)** | **Proposed**<br>**Maximum**<br>**Offering**<br>**Price Per**<br>**Unit** | **Maximum**<br>**Aggregate**<br>**Offering**<br>**Price** | **Fee**<br>**Rate** | **Amount of**<br>**Registration**<br>**Fee** |
| Equity | Common Stock, $0.0001 par value per share, Kura Oncology, Inc. Amended and Restated 2014 Equity Incentive Plan | Rule 457(c) and Rule 457(h) | 6500000(2) | $8.80(3) | $57200000.00(3) | 0.0001381 | $7899.32 |
| Equity | Common Stock, $0.0001 par value per share, Kura Oncology, Inc. Amended and Restated 2015 Employee Stock Purchase Plan | Rule 457(c) and Rule 457(h)<br>| 2500000(4) | $7.48(5) | $18700000.00(5) | 0.0001381 | $2582.47 |
| Total Offering Amounts |  |  |  |  | $75900000.00 |  | $10481.79 |
| Total Fee Offsets |  |  |  |  |  |  |  |
| Net Fee Due |  |  |  |  |  |  | $10481.79 |

---

(1)Pursuant to Rule 416(a) under the Securities Act of 1933, as amended (the "Securities Act"), this Registration Statement shall also cover any additional shares of the Registrant's Common Stock ("Common Stock") that become issuable under the Kura Oncology, Inc. Amended and Restated 2014 Equity Incentive Plan (the "2014 Plan") and the Kura Oncology, Inc. Amended and Restated 2015 Employee Stock Purchase Plan (the "2015 ESPP") by reason of any stock dividend, stock split, recapitalization or other similar transaction.

&nbsp;&nbsp;&nbsp;&nbsp;(2)Represents shares of Common Stock that were added to the shares authorized for issuance under the 2014 Plan on June 4, 2026 pursuant to stockholder approval of an amendment to the 2014 Plan.

&nbsp;&nbsp;&nbsp;&nbsp;(3)Estimate is made pursuant to Rule 457(h)(1) and Rule 457(c) of the Securities Act solely for purposes of calculating the registration fee. The price per share and aggregate offering price are based upon the average of the high and low prices of the Common Stock on June 3, 2026, as reported on the Nasdaq Global Select Market.

&nbsp;&nbsp;&nbsp;&nbsp;(4)Represents shares of Common Stock that were added to the shares authorized for issuance under the 2015 ESPP on June 4, 2026 pursuant to stockholder approval of an amendment to the 2015 ESPP.

&nbsp;&nbsp;&nbsp;&nbsp;(5)Estimate is made pursuant to Rule 457(h)(1) and Rule 457(c) of the Securities Act solely for purposes of calculating the registration fee. The price per share and aggregate offering price are based upon the average of the high and low prices of the Common Stock on June 3, 2026, as reported on the Nasdaq Global Select Market, multiplied by 85%, which is the percentage of the price per share applicable to purchases under the 2015 ESPP.

------